AtomVie Global Radiopharma Inc. joins the CNIC to bring new leadership, innovation, and collaboration to the radiopharmaceutical industry.

Toronto – November 2, 2022 – AtomVie Global Radiopharma Inc. (AtomVie), a manufacturer and supplier of multiple finished-dose therapeutic radiopharmaceutical products, is the newest member of the Canadian Nuclear Isotope Council (CNIC). AtomVie has developed over 7 years of experience in the GMP manufacturing and global distribution of radiopharmaceuticals as the former CMO business unit […]   READ MORE

Isotope Production System at Bruce Power commences Commercial Production of Lutetium-177

Toronto, Ontario – October 25, 2022 – Yesterday, the international partnership between Bruce Power, Isogen (a Kinectrics and Framatome company), and ITM Isotope Technologies Munich (ITM), announced the start of commercial production of lutetium-177. Lutetium-177 is a medical isotope used for targeted cancer therapies. The properties of the isotope allow it to bond with a […]   READ MORE

BWXT Medical Submits Tc-99m Generator New Drug Application to FDA

Company Highlights Growing Nuclear Medicine Product Portfolio and Future Opportunities in Therapeutic Radioisotopes (OTTAWA, ON – September 13, 2022) – BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. has submitted a new drug application to the U.S. Food and Drug Administration (FDA) to request approval of its technetium-99m (Tc-99m) generator for […]   READ MORE

The CNIC joins twenty leading organizations as part of a joint Industry Statement touting the benefits of nuclear isotopes.

Toronto – August 16, 2022 – The Canadian Nuclear Isotope Council (CNIC) is proud to participate in a joint Industry Statement to the Tenth Review Conference of the Parties to the Treaty on the Non-Proliferation of Nuclear Weapons (NPT) alongside international and national industry associations covering a wide variety of nuclear applications. The NPT importantly […]   READ MORE

BWXT Medical and TRIUMF Execute Agreement for Manufacture of High Purity Ac-225 Based Products

(OTTAWA, ON – June 13, 2022) – BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. and TRIUMF, Canada’s particle accelerator centre, have executed a licensing and services agreement that strengthens their existing partnership for the production of medical isotopes. This agreement will enable BWXT Medical to manufacture high purity Actinium-225 (Ac-225) […]   READ MORE